Axona is an innovative medical food designed to address an unmet need in Alzheimer's disease. Axona is not a drug, but is designed to address the cerebral hypometabolism that occurs decades before the diagnosis of Alzheimer's disease.1
Extensive evidence from years of research has established that glucose hypometabolism is a key underlying feature of the Alzheimer's brain.2 This leaves neurons less able to utilize glucose for fuel, leading to an energy shortage in the brain. This hypometabolism occurs early, is region-specific, and correlates with other clinical features.3-5
Axona helps address this deficiency by providing ketone bodies as an alternative fuel source for neurons. Ketone bodies are naturally produced by the liver from medium chain triglycerides as a back-up fuel when glucose levels are low. Adding Axona to Alzheimer's disease management addresses a critical aspect of the disease and may further enhance memory and cognition.6-7
Recently, a team at UCLA confirmed that daily ingestion of Axona over 45 days was associated with increased cerebral blood flow in Alzheimer's disease patients lacking the apolipoprotein ɛ4 allele, in a double-blinded, placebo-controlled, randomized clinical trial.8
All images © 2018 Elsevier. Torosyan et al (2018, October 1). Experimental Gerontology [Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study]. Retrieved September 29, 2018, from http://www.sciencedirect.com/journal/experimental-gerontology
Image above modified from Torosyan et al8 Long-term effects of 45 days of daily Axona on pre-dose rCBF in APOE4-negative (a) and APOE4-positive (b) groups. Regionally significant increases in cerebral cortex are depicted in the 3D representation of left cerebral hemisphere. Colorscale represents locations of all voxels undergoing increasing activity (p < 0.01), and higher density of the redness corresponds to closer proximity to the cortical surface displayed.
For more information please visit the Axona website